United Therapeutics (UTHR) Competitors $363.25 -23.02 (-5.96%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends UTHR vs. TEVA, RETA, BPMC, IONS, BHVN, ALNY, BIIB, INCY, BMRN, and NBIXShould you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Teva Pharmaceutical Industries (TEVA), Reata Pharmaceuticals (RETA), Blueprint Medicines (BPMC), Ionis Pharmaceuticals (IONS), Biohaven (BHVN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), BioMarin Pharmaceutical (BMRN), and Neurocrine Biosciences (NBIX). These companies are all part of the "medical" sector. United Therapeutics vs. Teva Pharmaceutical Industries Reata Pharmaceuticals Blueprint Medicines Ionis Pharmaceuticals Biohaven Alnylam Pharmaceuticals Biogen Incyte BioMarin Pharmaceutical Neurocrine Biosciences United Therapeutics (NASDAQ:UTHR) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, community ranking, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations. Do analysts recommend UTHR or TEVA? United Therapeutics currently has a consensus target price of $370.86, suggesting a potential upside of 2.09%. Teva Pharmaceutical Industries has a consensus target price of $19.67, suggesting a potential upside of 19.70%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than United Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score United Therapeutics 1 Sell rating(s) 2 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.73Teva Pharmaceutical Industries 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Do institutionals & insiders have more ownership in UTHR or TEVA? 94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 11.9% of United Therapeutics shares are owned by company insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is UTHR or TEVA more profitable? United Therapeutics has a net margin of 40.31% compared to Teva Pharmaceutical Industries' net margin of -5.73%. Teva Pharmaceutical Industries' return on equity of 42.92% beat United Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets United Therapeutics40.31% 19.22% 16.15% Teva Pharmaceutical Industries -5.73%42.92%7.25% Does the MarketBeat Community prefer UTHR or TEVA? Teva Pharmaceutical Industries received 735 more outperform votes than United Therapeutics when rated by MarketBeat users. Likewise, 67.77% of users gave Teva Pharmaceutical Industries an outperform vote while only 62.30% of users gave United Therapeutics an outperform vote. CompanyUnderperformOutperformUnited TherapeuticsOutperform Votes59062.30% Underperform Votes35737.70% Teva Pharmaceutical IndustriesOutperform Votes132567.77% Underperform Votes63032.23% Which has more volatility and risk, UTHR or TEVA? United Therapeutics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Does the media prefer UTHR or TEVA? In the previous week, United Therapeutics had 15 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 24 mentions for United Therapeutics and 9 mentions for Teva Pharmaceutical Industries. United Therapeutics' average media sentiment score of 1.17 beat Teva Pharmaceutical Industries' score of 1.08 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 17 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, UTHR or TEVA? United Therapeutics has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUnited Therapeutics$2.33B6.97$984.80M$22.7715.95Teva Pharmaceutical Industries$15.85B1.17-$559M-$0.85-19.33 SummaryUnited Therapeutics beats Teva Pharmaceutical Industries on 11 of the 18 factors compared between the two stocks. Ad WealthPressThe Tesla Trade Is Back In BusinessIf you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.Discover how to trade Tesla, simply follow this link here. Get United Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UTHR vs. The Competition Export to ExcelMetricUnited TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.24B$6.39B$5.07B$8.66BDividend YieldN/A8.08%5.10%4.06%P/E Ratio15.9510.92101.9217.45Price / Sales6.97245.131,198.0869.07Price / Cash17.4953.4940.9736.36Price / Book2.669.306.335.87Net Income$984.80M$154.14M$119.64M$225.66M7 Day Performance-11.40%-9.47%-5.13%-1.34%1 Month Performance-2.56%-7.30%-2.72%1.15%1 Year Performance58.67%28.21%31.08%24.02% United Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UTHRUnited Therapeutics4.514 of 5 stars$363.25-6.0%$370.86+2.1%+60.3%$16.22B$2.33B15.951,168Insider SellingNews CoveragePositive NewsTEVATeva Pharmaceutical Industries2.7975 of 5 stars$16.43-1.9%N/A+87.6%$18.61B$15.85B-19.3337,851Gap DownRETAReata PharmaceuticalsN/A$172.36+0.0%N/A+0.0%$6.58B$23.48M0.00321Analyst ForecastBPMCBlueprint Medicines3.0804 of 5 stars$88.69-7.3%N/A+41.6%$5.63B$249.38M-42.03640Analyst ForecastShort Interest ↑News CoverageIONSIonis Pharmaceuticals4.0875 of 5 stars$34.34-7.8%N/A-29.3%$5.42B$803.07M-14.07800Analyst DowngradeInsider SellingShort Interest ↑News CoverageBHVNBiohaven3.811 of 5 stars$44.39-8.8%N/A+49.6%$4.49B$462.51M-4.75239Earnings ReportAnalyst ForecastNews CoverageALNYAlnylam Pharmaceuticals4.8194 of 5 stars$235.56-8.7%N/A+39.4%$30.38B$1.83B-89.912,100Analyst DowngradeShort Interest ↓High Trading VolumeBIIBBiogen4.8855 of 5 stars$159.99-3.0%N/A-30.3%$23.31B$9.84B14.457,570Analyst UpgradeNews CoverageINCYIncyte4.1835 of 5 stars$75.87-2.4%N/A+40.5%$14.62B$3.70B541.972,524Analyst ForecastPositive NewsBMRNBioMarin Pharmaceutical4.9905 of 5 stars$63.42-3.3%N/A-27.3%$12.09B$2.42B37.983,401Analyst ForecastInsider SellingNews CoverageNBIXNeurocrine Biosciences4.9625 of 5 stars$117.44-4.4%N/A+8.0%$11.89B$2.24B31.491,400 Related Companies and Tools Related Companies TEVA Alternatives RETA Alternatives BPMC Alternatives IONS Alternatives BHVN Alternatives ALNY Alternatives BIIB Alternatives INCY Alternatives BMRN Alternatives NBIX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:UTHR) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free UTHR Stock Alerts